Other Mutations: RET

NCT05225259: Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

NCT05225259
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK, RET
Breast Cancer Tissue: 
Recruitment Status: Available

Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult))
Location of Metastases: 
Additional Notes: Patients must be medically suitable for treatment with LOXO-260, but not eligible or able to participate in an ongoing LOXO-260 clinical trial
Exclusions: 
https://ClinicalTrials.gov/show/NCT05225259

NCT04683250: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

NCT04683250
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RET
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase of the study
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases and/or leptomeningeal disease- see trial for details
https://ClinicalTrials.gov/show/NCT04683250

Up ↑